Article
Section
All sections
Countries | Regions
Countries | Regions
Article Types
Article Types
Year
Volume
Issue
Pages
IMR Press / EJGO / Volume 42 / Issue 5 / DOI: 10.31083/j.ejgo4205133
2
14
Views
Journal Browser
Volume | Year
Issue
Announcements
Open Access Original Research
Granzyme B expression correlates with poor prognosis in ovarian serous cystadenocarcinoma
Show Less
1 Obstetrics and Gynecology, the First Affiliated Hospital of Zhengzhou University, 450000 Zhengzhou, Henan, China
Eur. J. Gynaecol. Oncol. 2021 , 42(5), 871–880; https://doi.org/10.31083/j.ejgo4205133
Submitted: 1 June 2021 | Revised: 25 June 2021 | Accepted: 23 July 2021 | Published: 15 October 2021
Abstract

Objective: The purpose of this study was to explore the expression of Granzyme B (GZMB) and its impact on the survival and prognosis of patients with ovarian serous cystadenocarcinoma (OSC) and to evaluate whether it could be used as a potential prognostic marker for OSC. Methods: The study included 43 cases of high-grade serous ovarian cancer (HGSOC) and 415 cases of OSC. Immunohistochemical analysis was performed to assess GZMB expression in cancer tissues, and the biological functions of GZMB were explored through biometric analysis. Results: In HGSOC tissues, later Federation International of Gynecology and Obstetrics (FIGO) staging was associated with lower GZMB expression (p $<$ 0.05). Moreover, GZMB expression was significantly related to clinical stage, distant metastasis, histological grade, and survival status (p $<$ 0.05), whereas it was not related to age (p $>$ 0.05). GZMB was also identified as a regulator of the immune response in the tumour microenvironment. Conclusions: GZMB is closely related to the occurrence and development of OSC, participating in immune regulation; hence, it could be a potential prognostic biomarker of OSC.

Keywords
Biomarker
Granzyme B
Immunity
Prognosis
Figures
Fig. 1.
Share